Expansion potential ZARS Pharma has two FDA approved products with ongoing development and a pipeline in various stages, indicating opportunities to expand into new indications or geographies, and to leverage existing CHADD and Peel delivery technologies in adjacent topical anesthetic markets.

Strategic partnerships Existing collaboration with EuroCept for European distribution of Synera demonstrates a successful partner model that could be replicated with additional regional partners, distributors, or contract manufacturing organizations to accelerate market reach.

Pain management focus Specialization in topical anesthetics for procedural pain (venous access, injections, dermatologic procedures) positions ZARS to target clinics, ambulatory surgery centers, and dermatology practices seeking improved patient comfort and procedural efficiency.

Market readiness FDA approval of Pliaglis and the commercial traction of Synera indicate a validated product portfolio with near-term sales upside through expanded payer access, clinical adoption, and education to drive uptake in cosmetic and minor dermatology procedures.

Revenue scale fit With reported revenue in the mid-range and a lean employee base, ZARS can pursue scalable, partner-led sales strategies, leveraging existing products to cross-sell to dermatology and anesthesia-focused practices while pursuing additional licensing opportunities.